A new study has demonstrated the scalability of Carlsbad, Calif-based ChromaCode’s exclusive HDPCR technology to detect 20 biomarkers in a single well using conventional qPCR instruments.1 The research—a collaboration between ChromaCode and Scott Fraser, PhD, of the University of Southern California—demonstrates the potential reach of the HDPCR technology developed by ChromaCode to cover a broader range of disease targets.
The HDPCR technology could enable a 5x increase in analytical capacity on existing instrument—which could allow broader global accessibility to precision medicine at an economical cost.
“Our team has demonstrated the ability to multiplex 20 targets in a single qPCR sample, providing a path to scalable, affordable enhanced multiplex diagnostic assays in the future. More markers enable more information with an economical approach to guide precision medicine,” says Aditya Rajagopal, chief technology officer at ChromaCode.
“This technological leap forward will allow me to ask basic science and clinical questions in the future that I never could with standard multiplex PCR,” says Fraser. “With the significant increase in information, I will be able to ask more questions per sample without sacrificing throughput or speed and keep costs low because we will be able to run it on the equipment we already have.”
For more information, visit ChromaCode.
1. Jacky L, Yurk D, Alvarado J, et al. Robust multichannel encoding for highly multiplexed quantitative PCR. Anal. Chem. Epub. February 25, 2021. doi: 10.1021/acs.analchem.0c04626.